Importantly, our findings align with the study's central thesis that nAChR‐targeted interventions must be carefully tailored to cancer types demonstrating meaningful receptor involvement, as indiscriminate application could lead to suboptimal therapeutic outcomes. Here, CHRNA4 is linked to cancer.